1337965-33-9

Upstream product

• 50-00-0 formaldehyd 
• 1337965-31-7 trans-8-chloro-1-(4-phenyl-cyclohexyl)-4H,6H-2,3,5,10b-tetraaza-benzo[e]azulene-5-carboxylic acid tert-butyl ester 
• 1337965-91-9 trans-4-phenyl-cyclohexanecarboxylic acid hydrazide 
• 57750-81-9 4-chloro-2-(chloromethyl)-1-nitrobenzene 
• 73033-58-6 5-chloro-2-nitrobenzyl alcohol 
• 1226808-00-9 7-chloro-2-oxo-1,2,3,5-tetrahydrobenzo[1,4]diazepine-4-carboxylic acid tert-butyl ester 
• 1226807-99-3 [(2-amino-5-chlorobenzyl)-tert-butoxycarbonylamino]acetic acid ethyl ester 
• 1226807-98-2 [tert-butoxycarbonyl-(5-chloro-2-nitrobenzyl)amino]acetic acid ethyl ester 
• 1226807-97-1 7-chloro-2-thioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepine-4-carboxylic acid tert-butyl ester 
• 1082673-09-3 ethyl 4-phenylcyclohexane-1-carboxylate 
• 50608-35-0 (5-chloro-2-nitrobenzylamino)acetic acid ethyl ester 
• 1466-73-5 trans-4-phenylcyclohexanecarboxylic acid 

Relevant academic research and scientific papers

Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder

We recently reported the discovery of a potent, selective, and brain-penetrant V1a receptor antagonist, which was not suitable for full development. Nevertheless, this compound was found to improve surrogates of social behavior in adults with autism spect

ARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES

The present invention is concerned with aryl-cyclohexyl-tetraazabenzo[e]azulenes of formula I, wherein R1, R2 and R3 are as described herein. The compounds according to the invention act as Via receptor modulators, and in